10 Result(s)
within
Article
Crystal L. Mackall
Science, Humanities and Social Sciences, multidisciplinary
-
Article
Open AccessEngineered CD47 protects T cells for enhanced antitumour immunity
Adoptively transferred T cells and agents designed to block the CD47–SIRPα axis are promising cancer therapeutics that activate distinct arms of the immune system1,2. Here we administered anti-CD47 antibodies in ...
-
Article
Open AccessPublisher Correction: FOXO1 is a master regulator of memory programming in CAR T cells
-
Article
Open AccessFOXO1 is a master regulator of memory programming in CAR T cells
A major limitation of chimeric antigen receptor (CAR) T cell therapies is the poor persistence of these cells in vivo1. The expression of memory-associated genes in CAR T cells is linked to their long-term persis...
-
Article
Author Correction: CAR immune cells: design principles, resistance and the next generation
-
Article
Co-opting signalling molecules enables logic-gated control of CAR T cells
Although chimeric antigen receptor (CAR) T cells have altered the treatment landscape for B cell malignancies, the risk of on-target, off-tumour toxicity has hampered their development for solid tumours becaus...
-
Article
CAR immune cells: design principles, resistance and the next generation
The remarkable clinical activity of chimeric antigen receptor (CAR) therapies in B cell and plasma cell malignancies has validated the use of this therapeutic class for liquid cancers, but resistance and limit...
-
Article
Open AccessGD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas
Diffuse intrinsic pontine glioma (DIPG) and other H3K27M-mutated diffuse midline gliomas (DMGs) are universally lethal paediatric tumours of the central nervous system1. We have previously shown that the disialog...
-
Article
Immune receptor inhibition through enforced phosphatase recruitment
Antibodies that antagonize extracellular receptor–ligand interactions are used as therapeutic agents for many diseases to inhibit signalling by cell-surface receptors1. However, this approach does not directly pr...
-
Article
c-Jun overexpression in CAR T cells induces exhaustion resistance
Chimeric antigen receptor (CAR) T cells mediate anti-tumour effects in a small subset of patients with cancer1–3, but dysfunction due to T cell exhaustion is an important barrier to progress4–6. To investigate th...
-
Article
Open AccessCD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity
Adoptive immunotherapy using chimeric antigen receptor (CAR) expressing T cells targeting the CD19 B lineage receptor has demonstrated marked success in relapsed pre-B-cell acute lymphoblastic leukaemia (ALL)....
